Patents by Inventor Clint Sorensen

Clint Sorensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12011470
    Abstract: This disclosure provides cannabinoid preparations for human consumption that have proven clinical benefits. The preparations are made from full-spectrum hemp oil, which includes a mixture of cannabinoids that work synergistically to achieve the beneficial effects. The hemp oil is micellized, which increases intestinal absorption, resulting in higher potency and a more rapid onset of action. The micellized oil may be combined with micellized cinnamon or clove oil as a flavor enhancer. When consumed daily, the combination of using full spectrum hemp oil with micellization imparts the consumer with an improvement in well-being by several criteria. Benefits include a reduction in inflammatory cytokines, lowering in glucose levels, and weight loss. The micellized cannabinoid preparations of this invention improves sleep quality by extending the period of time spent in deep sleep.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: June 18, 2024
    Inventors: Clint Sorensen, Melanie Montgomery, Matt Smith
  • Patent number: 11826320
    Abstract: This disclosure provides a technology for managing elevated cytokine levels and the risk of cytokine storm in viral infection, exemplified by SARS-CoV-2, the virus that causes COVID-19. A special mixture of cannabidiol (CBD), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) is extracted from the flowers and leaves of Cannabis sativa (industrial hemp). The purified oil is packed with a surfactant into small micelles, which considerably increases absorption by the gastrointestinal tract, resulting in higher potency and a more rapid onset of action. Daily treatment of patients infected with SARS-CoV-2 reduces the circulating level of the pro-inflammatory cytokines tumor necrosis factor alpha (TNF?) and interleukin 6 (IL-6) by 25 to 50% or more. The level of circulating markers of ongoing inflammation, such as C reactive protein (CRP) and/or erythrocyte sedimentation rate (EST) are also reduced.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: November 28, 2023
    Assignee: WSMEF LLC
    Inventors: Clint Sorensen, Melanie Montgomery, Matt Smith
  • Publication number: 20230038771
    Abstract: This disclosure provides cannabinoid preparations for human consumption that have proven clinical benefits in patients infected with SARS-CoV-2 (the virus that causes COVID-19). The preparations are made from full-spectrum hemp oil, which includes a mixture of cannabinoids that work synergistically. The hemp oil is micellized with a median particle size of 22 nm in diameter, which considerably increases intestinal absorption, resulting in higher potency and a more rapid onset of action. Taken regularly, the preparation helps improve sleep quality by lengthening the time spent in deep sleep. In patients with COVID, the improved sleep quality is accompanied by a lower risk of cytokine storm.
    Type: Application
    Filed: March 31, 2022
    Publication date: February 9, 2023
    Inventors: Clint Sorensen, Melanie Montgomery, Matt Smith
  • Publication number: 20220031635
    Abstract: This disclosure provides a technology for managing elevated cytokine levels and the risk of cytokine storm in viral infection, exemplified by SARS-CoV-2, the virus that causes COVID-19. A special mixture of cannabidiol (CBD), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) is extracted from the flowers and leaves of Cannabis sativa (industrial hemp). The purified oil is packed with a surfactant into small micelles, which considerably increases absorption by the gastrointestinal tract, resulting in higher potency and a more rapid onset of action. Daily treatment of patients infected with SARS-CoV-2 reduces the circulating level of the pro-inflammatory cytokines tumor necrosis factor alpha (TNF?) and interleukin 6 (IL-6) by 25 to 50% or more. The level of circulating markers of ongoing inflammation, such as C reactive protein (CRP) and/or erythrocyte sedimentation rate (EST) are also reduced.
    Type: Application
    Filed: July 29, 2021
    Publication date: February 3, 2022
    Inventors: Clint Sorensen, Melanie Montgomery, Matt Smith